Press Releases

Aurora BioPharma, Inc. CEO Attends The Annual ImVacS


CAMBRIDGE, MA - August 24, 2015 - Aurora BioPharma, Inc. announces that its Chief Executive Officer, Robert Brooks, will attend the 10th Annual ImVacS: Immunotherapy and Vaccine Summit on August 24 - 28, 2015 in Boston, Massachusetts presented by the Cambridge Healthtech Institute. The event attracts over 300 international delegates from biotech and pharma every year. This year's gathering will cover vaccine, immunotherapy technologies, immunomodulatory therapeutic antibodies for cancer, combination cancer immunotherapy and others. ImVacS 2015 promises to be a prominent gathering for academic and healthcare professionals in the advancement of immunotherapies and vaccines through innovation.

About Cambridge Healthtech Institute

Cambridge Healthtech Institute is the preeminent life science network for leading scientists and healthcare entities comprising major biotech, pharmaceutical and academic organizations. CHI's portfolio includes Cambridge Healthtech Institute Conferences, Barnett Educational Services, Cambridge Marketing Consultants, Insight Pharma Reports, Cambridge Meeting Planners and CHI's Media Group, which includes Bio-IT World and Clinical Informatics News. Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments.

About Aurora BioPharma, Inc.

Aurora is a biotechnology company based in Cambridge, Massachusetts commercializing cutting-edge cancer immunotherapy drugs in FDA human clinical trials. Aurora's portfolio includes: MX-225, an autologous P53 dendritic cell vaccine that completed two Phase IIa trials in Small Cell Lung Cancer (SCLC), and recurring breast cancer. The company is planning a Phase II SCLC combination trial with MX-225 and a PD-1 antibody and developing a car-t therapy. Another one of Aurora's drugs in clinic is MX-402 - a unique B-cell epitope HER-2 Peptide vaccine that had showed safety and strong signals of efficacy in an interim Phase I trial. Eight of twelve patients showed clinical benefit, with one patient in complete remission. Aurora's team is comprised of world renowned scientists and biotech industry professionals.

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For media inquiries, please contact:

Candace Cobos

VP, Business Development & Public Relations

Harvard Square, One Mifflin Place, Suite 400

Cambridge, MA 02138

Tel: (617) 674-7718 - Fax: (617) 674-7701

Ingraham Building, 25 SE 2nd Avenue, Suite 504

Miami, FL 33131

Tel: (305) 371-2301 - Fax: (305) 371-2304 -

New Paradigm in Cancer Immunotherapy

Source: Aurora BioPharma, Inc.